secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2026-02-20T23:59:59+00:00
Accession:  0001683168-26-001216
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Majority shareholder approves reverse stock split up to 1-for-10 for Sunshine Biopharma
--------------------------------------------------------------------------------

- Dr. Steve N. Slilaty, holding ~96% voting power, approved by written consent a reverse split of common stock up to 1-for-10.
- Board has discretion on whether to effect the reverse split and the exact ratio (whole number up to 1-for-10).
- Shareholder consent will be effective 20 days after mailing definitive information statement to stockholders.
- Dr. Slilaty is CEO and controls approximately 96% of total voting power.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826001216/0001683168-26-001216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316826001216/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-001216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer